Clinical stage drug development company focused on next generation DNA Damage Response (DDR) therapeutics Senhwa Biosciences, Inc. (TPEx: 6492) announced on Friday that its drug Silmitasertib (CX-4945) received Rare Paediatric Disease Designation (RPDD) from the US FDA for neuroblastoma treatment.
This follows a previous RPDD granted for medulloblastoma in July 2020, underscoring Silmitasertib's potential in rare pediatric cancers. Silmitasertib, a first-in-class CK2 inhibitor, demonstrated antitumor activity in pre-clinical neuroblastoma studies.
The RPDD qualifies the drug for the Priority Review Voucher (PRV) program, designed to accelerate the development of novel therapies for rare pediatric diseases. Silmitasertib has already been granted one RPDD and three Orphan Drug Designations (ODD) by the FDA.
Neuroblastoma, predominantly affecting infants and diagnosed on average between 1 and 2 years old, represents the third most common pediatric cancer in the US, with 700 to 800 new cases annually. High-risk neuroblastoma has a 5-year survival rate of approximately 50% and is prone to recurrence despite intensive treatment; no standard treatment exists for relapsed or refractory cases.
NCI reports IND submission for pilot study of Senhwa Biosciences Inc's developed Pidnarulex
Epitomee Medical's Capsule cleared by FDA for weight management
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Neuspera Medical names new chief operating officer
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024